T
VIVO

Thomaspartners’s Meridian Bioscience Inc VIVO Stock Holding History

Thomaspartners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,430
Closed -$205K – 145
2014
Q1 		$205K Hold
9,430
– – ﹤0.01% 134
2013
Q4 		$250K Buy
+9,430
New +$232K 0.01% 121
2013
Q3 		– Sell
-12,816
Closed -$276K – 197
2013
Q2 		$276K Buy
+12,816
New +$276K 0.01% 124

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
PIM
Perkins Investment Management Chicago, Illinois $8.09B AUM 25.47% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Thomaspartners's VIVO Position: Q2 2014 in Review

Thomaspartners sold out of Meridian Bioscience Inc (VIVO) in Q2 2014, closing a stake of 9,430 shares — an estimated $205K sold.

Thomaspartners first reported a position in VIVO in Q2 2013 and held it in 3 quarters. The position peaked at $276K in Q2 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q2 2014.

  • Thomaspartners reported no remaining Meridian Bioscience Inc position as of Q2 2014 after selling out during the quarter.
  • Thomaspartners sold 9,430 Meridian Bioscience Inc shares in Q2 2014, an estimated $205K.
  • Thomaspartners first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 3 quarters.
  • Thomaspartners's Meridian Bioscience Inc position peaked at $276K in Q2 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2014.

Based on Thomaspartners's 13F filing for Q2 2014, filed 30 Jul 2014.